Accordingly it is currently looking for two software engineers to join the team - one to head up our UI development with Flex/Flash skills and the second to head up development of our client based products with expertise in C/C++/Java. We will consider strong candidates at any time but applications on or prior to 14th April 2010

Dr Douglas Armstrong, Actual Analytics  CSO (right), said “The financial and mentoring support we have been given by the Scottish Enterprise Proof of Concept and University of Edinburgh ProsPeKT programmes have been invaluable in enabling us to translate our research into this high potential business.”

Disorders of the nervous system affect 1 in 3 people during their lives, account for the largest single burden on the NHS, often long-term disabling illnesses for the patient, their friends and family. At an estimated cost of over US$800m to take a new drug to market, Actual Analytics’ product will help customers cut costs and remove a significant bottleneck in the drug discovery pipeline.

Actual Analytics CEO, James Heward, said “This... allows us to commercialise this groundbreaking research, creating a product that will make a significant difference to organisations around the world working hard to develop revolutionary drugs.”

The technology has been validated with some of the world’s leading pharmaceutical companies and academic laboratories across North America, Asia and Europe, and it is expected that these organisations will become early customers.

The product is the culmination of over 5 years of research within Edinburgh University’s School of Informatics, Europe’s largest and most highly rated computer science department. Funding for the
project to date has included a 2-year Scottish Enterprise Proof of Concept award and significant in-kind assistance from Informatics Ventures.